Castle Biosciences (CSTL)
(Delayed Data from NSDQ)
$30.36 USD
-0.89 (-2.85%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $30.32 -0.04 (-0.13%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Balance Sheet
Fiscal Year End for Castle Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 243 | 259 | 330 | 410 | 99 |
Receivables | 38 | 23 | 17 | 13 | 15 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 8 | 4 | 2 | 2 | 1 |
Other Current Assets | 6 | 6 | 5 | 5 | 2 |
Total Current Assets | 296 | 292 | 354 | 430 | 117 |
Net Property & Equipment | 25 | 14 | 10 | 7 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 1 | 1 | 1 | 1 | 1 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 117 | 126 | 89 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 2 | 2 | 0 |
Total Assets | 453 | 447 | 463 | 439 | 120 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 10 | 5 | 3 | 2 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 6 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 36 | 30 | 21 | 12 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 7 | 0 |
Total Current Liabilities | 48 | 36 | 25 | 21 | 15 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 1 | 1 | 1 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 19 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 18 | 2 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 62 | 48 | 51 | 24 | 35 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 609 | 560 | 505 | 478 | 137 |
Retained Earnings | -218 | -161 | -94 | -63 | -52 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 391 | 399 | 412 | 416 | 85 |
Total Liabilities & Shareholder's Equity | 453 | 447 | 463 | 439 | 120 |
Total Common Equity | 391 | 399 | 412 | 416 | 85 |
Shares Outstanding | 26.90 | 26.30 | 25.30 | 20.10 | 17.00 |
Book Value Per Share | 14.55 | 15.18 | 16.27 | 20.68 | 5.01 |
Fiscal Year End for Castle Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 260 | 239 | 243 | 230 | 226 |
Receivables | 46 | 43 | 38 | 37 | 31 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 8 | 8 | 8 | 6 | 6 |
Other Current Assets | 7 | 6 | 6 | 7 | 6 |
Total Current Assets | 320 | 296 | 296 | 280 | 269 |
Net Property & Equipment | 39 | 33 | 25 | 22 | 21 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 1 | 1 | 1 | 1 | 1 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 113 | 115 | 117 | 120 | 122 |
Deposits & Other Assets | 3 | 2 | 1 | 2 | 1 |
Total Assets | 487 | 459 | 453 | 436 | 425 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 10 | 9 | 10 | 7 | 7 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 29 | 21 | 36 | 28 | 25 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 39 | 32 | 48 | 36 | 34 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 10 | 10 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 63 | 56 | 62 | 50 | 47 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 636 | 623 | 609 | 602 | 588 |
Retained Earnings | -212 | -221 | -218 | -216 | -209 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 424 | 402 | 391 | 386 | 379 |
Total Liabilities & Shareholder's Equity | 487 | 459 | 453 | 436 | 425 |
Total Common Equity | 424 | 402 | 391 | 386 | 379 |
Shares Outstanding | 27.60 | 27.60 | 26.90 | 26.90 | 26.80 |
Book Value Per Share | 15.36 | 14.58 | 14.55 | 14.34 | 14.13 |